Javascript Disabled

This site requires Javascript in order to function properly. Please enable it in your browser's settings.

To reduce serum phosphate in patients with ESRD FOSRENOL Chewable Tablets:
Separate studies have demonstrated that FOSRENOL effectively reduced serum phosphate in ESRD patients.1


Phosphorus reductions maintained for up to 3 years in patients who received FOSRENOL throughout the study (n=46)1,3,4

Safety results in long-term extension studies2

  • In the initial 6-month extension, 23% of patients discontinued because of adverse events; the most common adverse events included nausea (15%), vomiting (14%), diarrhea (12%), hypotension (11%), and cramps (11%)
  • In the optional 2-year extension, 2.4% of adverse events led to withdrawal; the most common adverse events included diarrhea (4%), abdominal pain (3%), and nausea (3%)

Significant serum phosphorus reductions in a separate clinical trial5

Safety results in the 11-week study5

  • Most common adverse events during randomized treatment were nausea (6.0% vs 4.5%, FOSRENOL vs placebo), vomiting (6.0% vs 2.3%), diarrhea (4.0% vs 6.8%), and dialysis graft occlusion (6.0% vs 2.3%)

Learn about FOSRENOL Oral Powder

Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Please click here for Full Prescribing Information .

Important Safety Information

Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Please click here for Full Prescribing Information.

References: 1. FOSRENOL [package insert]. Lexington, MA: Shire US Inc. 2. Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract. 2006;102:c61-c71. 3. Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005;100:c8-c19. 4. Data on file, Shire US Inc., SPD405-04. 5. Joy MS, Finn WF; LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003;42:96-107.